Pharmaceutical Acquisition

Stock futures are poised to rebound, driven by potential de-escalation in the Middle East following US-Iran negotiation signals. Key developments also include Meta being found liable for civil damages, OpenAI shutting down Sora and securing significant funding, progress on a government funding stalemate, and Merck acquiring Terns Pharmaceuticals to bolster its pipeline. These geopolitical, legal, and corporate moves are shaping a dynamic trading day.

Metsera Inc. has announced an amended merger agreement with Pfizer, valued at up to $86.25 per share, comprising $65.60 upfront and a contingent value right (CVR) of up to $20.65 based on milestones. The Metsera Board unanimously recommends shareholder approval, citing optimal value and deal certainty. This decision follows concerns raised by the U.S. Federal Trade Commission regarding a previous deal with Novo Nordisk. The board prioritizes the Pfizer merger due to its expectation of swift closure and immediate value delivery to shareholders.